Search

Your search keyword '"Fagerli, Unn Merete"' showing total 240 results
Start Over Author "Fagerli, Unn Merete"
240 results on '"Fagerli, Unn Merete"'

5. Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up

Author

Pulczynski, Elisa Jacobsen, primary, Simonsen, Mikkel Runason, additional, Kuittinen, Outi, additional, Fagerli, Unn-Merete, additional, Erlanson, Martin, additional, Fluge, Øystein, additional, Leppä, Sirpa, additional, Østenstad, Bjørn, additional, Fosså, Alexander, additional, Eriksson, Mikael, additional, El-Galaly, Tarec, additional, Kuitunen, Hanne, additional, Papworth, Karin, additional, Ljungqvist, Maria, additional, Pedersen, Martin B., additional, and Pollari, Marjukka, additional

Published
2024
Full Text
View/download PDF

6. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Author

Leppä, Sirpa, Jørgensen, Judit, Tierens, Anne, Meriranta, Leo, Østlie, Ingunn, de Nully Brown, Peter, Fagerli, Unn-Merete, Larsen, Thomas Stauffer, Mannisto, Susanna, Munksgaard, Lars, Maisenhölder, Martin, Vasala, Kaija, Meyer, Peter, Jerkeman, Mats, Björkholm, Magnus, Fluge, Øystein, Jyrkkiö, Sirkku, Liestøl, Knut, Ralfkiaer, Elisabeth, Spetalen, Signe, Beiske, Klaus, Karjalainen-Lindsberg, Marja-Liisa, and Holte, Harald

Published
2020
Full Text
View/download PDF

10. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Author

Kolstad, Arne, Pedersen, Lone Bredo, Eskelund, Christian W., Husby, Simon, Grønbæk, Kirsten, Jerkeman, Mats, Laurell, Anna, Räty, Riikka, Elonen, Erkki, Andersen, Niels Smedegaard, Brown, Peter deNully, Kimby, Eva, Bentzen, Hans, Sundström, Christer, Ehinger, Mats, Karjalainen-Lindsberg, Marja-Liisa, Delabie, Jan, Ralfkiær, Elisabeth, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Kuittinen, Outi, Niemann, Carsten, and Geisler, Christian Hartman

Published
2017
Full Text
View/download PDF

12. Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Author

Leppa, Sirpa, primary, Jørgensen, Judit M., additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Beiske, Klaus, additional, Pedersen, Mette, additional, Drott, Kristina, additional, Pasanen, Annika, additional, Karihtala, Kristiina, additional, Mannisto, Susanna, additional, Meriranta, Leo, additional, Wold, Bente, additional, Brodtkorb, Marianne, additional, Fagerli, Unn Merete, additional, Larsen, Thomas S., additional, Munksgaard, Lars, additional, Sunela, Kaisa, additional, Fluge, Øystein, additional, Jyrkkio, Sirkku, additional, Brown, Peter de Nully, additional, and Holte, Harald, additional

Published
2022
Full Text
View/download PDF

13. Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Author

Relander, Thomas, primary, Pedersen, Martin Bjerregård, additional, Ellin, Fredrik, additional, Lauritzsen, Grete Fossum, additional, Jantunen, Esa, additional, Hagberg, Hans, additional, Holte, Harald, additional, Österborg, Anders, additional, Brown, Peter De Nully, additional, Kuittinen, Outi, additional, Erlanson, Martin, additional, Ostenstad, Bjorn, additional, Fagerli, Unn-Merete, additional, Delabie, Jan, additional, Sundström, Christer, additional, Sander, Birgitta, additional, Hamilton-Dutoit, Stephen, additional, Ehinger, Mats, additional, Liestol, Knut, additional, Toldbod, Helle, additional, Feldman, Andrew L., additional, and d'Amore, Francesco Annibale, additional

Published
2022
Full Text
View/download PDF

14. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Author

Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Grønbæk, Kirsten, Elonen, Erkki, Räty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Kimby, Eva, Hansen, Per Boye, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundstrom, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, and Geisler, Christian H.

Published
2014
Full Text
View/download PDF

16. Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life

Author

Smeland, Knut, primary, Holte, Harald, additional, Fagerli, Unn-Merete, additional, Bersvendsen, Hanne, additional, Hjermstad, Marianne J., additional, Loge, Jon H., additional, Murbrach, Klaus, additional, Linnsund, Marianne D., additional, Fluge, Oystein, additional, Stenehjem, Jo S., additional, Lund, May B., additional, Kvaloy, Stein, additional, and Kiserud, Cecilie E., additional

Published
2022
Full Text
View/download PDF

19. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials : MCL2 and MCL3

Author

Eskelund, Christian Winther, Dimopoulos, Kostas, Kolstad, Arne, Glimelius, Ingrid, Raty, Riikka, Gjerdrum, Lise Mette Rahbek, Sonnevi, Kristina, Josefsson, Par, Nilsson-Ehle, Herman, Bentzen, Hans H. N., Fagerli, Unn Merete, Kuittinen, Outi, Haaber, Jacob, Niemann, Carsten Utoft, Pedersen, Lone Bredo, Larsen, Maria Torp, Geisler, Christian Hartmann, Hutchings, Martin, Jerkeman, Mats, Gronbaek, Kirsten, Eskelund, Christian Winther, Dimopoulos, Kostas, Kolstad, Arne, Glimelius, Ingrid, Raty, Riikka, Gjerdrum, Lise Mette Rahbek, Sonnevi, Kristina, Josefsson, Par, Nilsson-Ehle, Herman, Bentzen, Hans H. N., Fagerli, Unn Merete, Kuittinen, Outi, Haaber, Jacob, Niemann, Carsten Utoft, Pedersen, Lone Bredo, Larsen, Maria Torp, Geisler, Christian Hartmann, Hutchings, Martin, Jerkeman, Mats, and Gronbaek, Kirsten

Abstract

Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The prognosis after relapse is generally poor, and no standard of care exists. We investigated the postrelapse outcomes of 149 patients who were initially treated in the Nordic Lymphoma Group trials, MCL2 or MCL3, both representing intensive cytarabine-containing frontline regimens including autologous stem cell transplant. Patients with progression of disease before 24 months (POD24, n = 51, 34%) displayed a median overall survival of 6.6 months compared with 46 months for patients with later POD (n = 98, 66%; P < 0.001). MCL international prognostic index, cell proliferation marker, blastoid morphology, and TP53 mutations showed independent prognostic value irrespective of POD24, and in a combined, exploratory risk score, patients with 0, 1, 2-3, or 4-5 high-risk markers, respectively, displayed a 5-year overall survival of 62%, 39%, 31%, and 0%. By a comparison of median progression-free survival of the different salvage therapies in the relapse setting, bendamustine-rituximab was superior to all other combination chemotherapy regimens; however, it was also associated with longer responses to last line of therapy. Collectively, we confirm the prognostic impact of POD24 and highlight the relevance of other biomarkers, and we emphasize the importance of novel therapies for patients with high-risk features at first POD.

Published
2021
Full Text
View/download PDF

24. Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

Author

Eskelund, Christian Winther, primary, Dimopoulos, Kostas, additional, Kolstad, Arne, additional, Glimelius, Ingrid, additional, Räty, Riikka, additional, Gjerdrum, Lise Mette Rahbek, additional, Sonnevi, Kristina, additional, Josefsson, Pär, additional, Nilsson-Ehle, Herman, additional, Bentzen, Hans H. N., additional, Fagerli, Unn Merete, additional, Kuittinen, Outi, additional, Haaber, Jacob, additional, Niemann, Carsten Utoft, additional, Pedersen, Lone Bredo, additional, Larsen, Maria Torp, additional, Geisler, Christian Hartmann, additional, Hutchings, Martin, additional, Jerkeman, Mats, additional, and Grønbæk, Kirsten, additional

Published
2020
Full Text
View/download PDF

25. Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress

Author

Bersvendsen, Hanne Skjerven, primary, Haugnes, Hege Sagstuen, additional, Dahl, Alv A., additional, Fagerli, Unn-Merete, additional, Fluge, Øystein, additional, Holte, Harald, additional, Wilsgaard, Tom, additional, Smeland, Knut Bjøro, additional, and Kiserud, Cecilie Essholt, additional

Published
2020
Full Text
View/download PDF

28. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Author

Kolstad, Arne, primary, Illidge, Tim, additional, Bolstad, Nils, additional, Spetalen, Signe, additional, Madsbu, Ulf, additional, Stokke, Caroline, additional, Blakkisrud, Johan, additional, Løndalen, Ayca, additional, O'Rourke, Noelle, additional, Beasley, Matthew, additional, Jurczak, Wojciech, additional, Fagerli, Unn-Merete, additional, Kaščák, Michal, additional, Bayne, Mike, additional, Obr, Aleš, additional, Dahle, Jostein, additional, Rojkjaer, Lisa, additional, Pascal, Veronique, additional, and Holte, Harald, additional

Published
2020
Full Text
View/download PDF

33. Runaway Train: A Leaky Radiosensitive SCID with Skin Lesions and Multiple Lymphomas

Author

Fevang, Børre, Fagerli, Unn Merete, Sorte, Hanne, Aarset, Harald, Hov, Håkon, Langmyr, Marit, Keil, Thomas Morten, Bjørge, Ellen, Aukrust, Pål, Stray-Pedersen, Asbjørg, and Gedde-Dahl, Tobias

Subjects
Article Subject
Abstract

The nuclease Artemis is essential for the development of T-cell and B-cell receptors and repair of DNA double-strand breaks, and a loss of expression or function will lead to a radiosensitive severe combined immunodeficiency with no functional T-cells or B-cells (T-B-SCID). Hypomorphic mutations in the Artemis gene can lead to a functional, but reduced, T-cell and B-cell repertoire with a more indolent clinical course called “leaky” SCID. Here, we present the case of a young man who had increasingly aggressive lymphoproliferative skin lesions from 2 years of age which developed into multiple EBV+ B-cell lymphomas, where a hypomorphic mutation in the Artemis gene was found in a diagnostic race against time using whole exome sequencing. The patient was given a haploidentical stem cell transplant while in remission for his lymphomas and although the initial course was successful, he succumbed to a serious Pneumocystis jirovecii pneumonia 5 months after the transplant. The case underscores the importance of next-generation sequencing in the diagnosis of patients with suspected severe immunodeficiency.

Published
2018
Full Text
View/download PDF

37. Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Author

d'Amore, Francesco, primary, Leppä, Sirpa, additional, Silva, Maria Gomes da, additional, Relander, Thomas, additional, Lauritzsen, Grete Fossum, additional, Brown, Peter De Nully, additional, Pezzutto, Antonio, additional, Doorduijn, Jeanette K., additional, Weidmann, Eckhart, additional, van Gelder, Michel, additional, Hoof, Achiel Van, additional, Christiansen, Ilse, additional, Fagerli, Unn Merete, additional, Hagberg, Hans, additional, Lugtenburg, P.J., additional, Walewski, Jan, additional, Wu, Ka Lung, additional, Demuynck, Hilde Maria, additional, Fijnheer, Rob, additional, Christensen, Jacob H., additional, Jankovská, Milada, additional, Josefsson, Pär L., additional, Kluin-Nelemans, Hanneke, additional, Mariz, Jose Mario, additional, Merup, Mats A., additional, Noesslinger, Thomas, additional, Van Den Neste, Eric, additional, Zijlstra, Josée M, additional, Hopfinger, Georg, additional, Prochazka, VIT, additional, Jantunen, Esa, additional, Boudova, Ludmila, additional, Cabecadas, Jose, additional, Chott, Andreas, additional, Delabie, Jan M.A., additional, de Leval, Laurence, additional, Diepstra, Arjan, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, Noergaard, Peter, additional, Rosenwald, Andreas, additional, Rymkiewicz, Grzegorz, additional, Sundström, Christer, additional, Truemper, Lorenz, additional, Wulf, Gerald, additional, Chong, Lauren, additional, Bouska, Alyssa, additional, Smith, Lynette, additional, Gisselbrecht, Christian, additional, Ziepert, Marita, additional, Loeffler, Markus, additional, Liestol, Knut, additional, Steidl, Christian, additional, Gascoyne, Randy D., additional, Scott, David W., additional, Altmann, Bettina, additional, Iqbal, Javeed, additional, Chan, Wing C, additional, and Toldbod, Helle, additional

Published
2018
Full Text
View/download PDF

38. LYMRIT 37-01: A Phase I/II Study of 177lu-Lilotomab Satetraxetan (Betalutin®) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Author

Kolstad, Arne, primary, Madsbu, Ulf, additional, Beasley, Matthew, additional, Bayne, Michael, additional, Illidge, Tim M., additional, O'Rourke, Noelle, additional, Lagerlöf, Ingemar, additional, Hajek, Roman, additional, Jurczak, Wojciech, additional, Willenbacher, Ella, additional, Fagerli, Unn Merete, additional, Obr, Aleš, additional, Blakkisrud, Johan, additional, Muftuler Løndalen, Ayca, additional, Rojkjaer, Lisa, additional, Østengen, Åse, additional, Bolstad, Nils, additional, Spetalen, Signe, additional, Erlanson, Martin, additional, Galleberg, Renate, additional, Nygaard Rudå, Stine, additional, and Holte, Harald, additional

Published
2018
Full Text
View/download PDF

39. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Author

Kolstad, Arne, Pedersen, Lone Bredo, Eskelund, Christian W., Husby, Simon, Gronbaek, Kirsten, Jerkeman, Mats, Laurell, Anna, Räty, Riikka, Elonen, Erkki, Andersen, Niels Smedegaard, Brown, Peter deNully, Kimby, Eva, Bentzen, Hans, Sundstrom, Christer, Ehinger, Mats, Karjalainen-Lindsberg, Marja-Liisa, Delabie, Jan, Ralfkiaer, Elisabeth, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Kuittinen, Outi, Niemann, Carsten, Geisler, Christian Hartman, Nordic Lymphoma Grp, Hematologian yksikkö, Clinicum, Department of Oncology, Department of Medicine, University of Helsinki, Medicum, Department of Pathology, and HUS Comprehensive Cancer Center

Subjects
Oncology, Male, Neoplasm, Residual, Lymphoma, Mantle-Cell, 0302 clinical medicine, Autologous stem-cell transplantation, Recurrence, hemic and lymphatic diseases, NETWORK, Hematopoietic Stem Cell Transplantation, TIME QUANTITATIVE PCR, Preemptive rituximab, Hematology, Middle Aged, Autologous stem cell, 3. Good health, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, Rituximab, Female, medicine.drug, PROGRESSION-FREE SURVIVAL, Adult, medicine.medical_specialty, 3122 Cancers, PHASE-2, Scandinavian and Nordic Countries, IMMUNOCHEMOTHERAPY, Transplantation, Autologous, 03 medical and health sciences, Median follow-up, Internal medicine, MULTIPLE-MYELOMA, medicine, Humans, PROGNOSTIC INDEX, Aged, Mantle cell lymphoma, business.industry, Minimal residual disease, REMISSION, medicine.disease, RANDOMIZED-TRIALS, Survival Analysis, Surgery, Lymphoma, body regions, 3121 General medicine, internal medicine and other clinical medicine, Immunoglobulin heavy chain, Bone marrow, business, 030215 immunology, transplantation, Follow-Up Studies
Abstract

The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rearrangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P .0001). OS was 75% at 10 years and median not reached in the MRD-negative group, compared with only 35 months in the MRD-positive group (P .0001). Of the 86 patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after 10 years. For all patients, the median time from ASCT to first molecular relapse was 55 months, with a continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from first molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients in the first analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies.

Published
2016

40. Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011–2016.

Author

Fosså, Alexander, Smeland, Knut, Fagerli, Unn-Merete, Galleberg, Renate B., Bersvendsen, Hanne S., and Holte, Harald

Subjects
HODGKIN'S disease treatment, THERAPEUTIC use of monoclonal antibodies, CANCER relapse, COMBINATION drug therapy, CHI-squared test, CONFIDENCE intervals, HEMATOPOIETIC stem cell transplantation, HODGKIN'S disease, IMIDAZOLES, MONOCLONAL antibodies, POSTOPERATIVE period, TREATMENT effectiveness, RETROSPECTIVE studies, KAPLAN-Meier estimator, LOG-rank test, MANN Whitney U Test, DISEASE risk factors
Abstract

The article describes the experience with Brentuximab vedotin (BV) antibody-drug conjugate in r/r cHL in Norway for patients treated with the approved indications from 2011 to 2016. Highlights include consolidation of responses to BV achieved through radiotherapy in isolated patients, approval of the study by the South East Regional Committee for Medical and Health Research Ethics, and comparison of patients treated with BV and a population-based historical cohort.

Published
2020
Full Text
View/download PDF

41. Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity

Author

Smeland, Knut B., primary, Loge, Jon H., additional, Aass, Hans C. D., additional, Aspelin, Trude, additional, Bersvendsen, Hanne, additional, Bolstad, Nils, additional, Fagerli, Unn-Merete, additional, Falk, Ragnhild S., additional, Fluge, Øystein, additional, Fosså, Alexander, additional, Holte, Harald, additional, Lund, May B., additional, Murbræch, Klaus, additional, Reinertsen, Kristin V., additional, Stenehjem, Jo S., additional, and Kiserud, Cecilie E., additional

Published
2018
Full Text
View/download PDF

42. Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial)

Author

Leppa, Sirpa, primary, Joergensen, Judit, additional, Tierens, Anne, additional, Østlie, Ingunn, additional, Fagerli, Unn Merete, additional, Brown, Peter de Nully, additional, Larsen, Thomas S, additional, Mannisto, Susanna, additional, Munksgaard, Lars, additional, Maisenhölder, Martin, additional, Vasala, Kaija, additional, Meyer, Peter, additional, Jerkeman, Mats, additional, Bjorkholm, Magnus, additional, Fluge, Oystein, additional, Jyrkkio, Sirkku, additional, Ralfkiaer, Elisabeth, additional, Spetalen, Signe, additional, Karjalainen-Lindsberg, Marja-Liisa, additional, and Holte, Harald, additional

Published
2016
Full Text
View/download PDF

44. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance : results from a phase II study by The Nordic Lymphoma Group

Author

Pulczynski, Elisa J., Kuittinen, Outi, Erlanson, Martin, Hagberg, Hans, Fossa, Alexander, Eriksson, Mikael, Nordstrom, Marie, Ostenstad, Bjorn, Fluge, Oystein, Leppa, Sirpa, Fiirgaard, Bente, Bersvendsen, Hanne, Fagerli, Unn-Merete, Pulczynski, Elisa J., Kuittinen, Outi, Erlanson, Martin, Hagberg, Hans, Fossa, Alexander, Eriksson, Mikael, Nordstrom, Marie, Ostenstad, Bjorn, Fluge, Oystein, Leppa, Sirpa, Fiirgaard, Bente, Bersvendsen, Hanne, and Fagerli, Unn-Merete

Abstract

The Nordic Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous system lymphoma patients applying an age-adjusted multi-agent immunochemotherapy regimen, which in elderly patients included temozolomide maintenance treatment. Patients aged 18-75 years were eligible. Thirty-nine patients aged 18-65 years and 27 patients aged 66-75 years were enrolled. The median age of the two age groups was 55 and 70 years, respectively. The overall response rate was 73.8% for the entire cohort: 69.9% in the younger and 80.8% in the elderly subgroup. With a median follow up of 22 months, the 2-year overall survival probability was 60.7% in patients aged 65 years or under and 55.6% in patients aged over 65 years (P=0.40). The estimated progression-free survival at two years was 33.1% (95% CI: 19.1%-47.9%) in patients aged under 65 years and 44.4% (95% CI: 25.6%-61.8%) in the elderly subgroup (P=0.74). Median duration of response was ten months in the younger subgroup, and not reached in the elderly patient subgroup (P=0.33). Four patients aged 64-75 years (6%) died from treatment-related complications. Survival in the two age groups was similar despite a de-escalation of induction treatment in patients aged over 65 years. Duration of response in elderly patients receiving maintenance temozolomide was longer than in the younger age subgroup. While toxicity during induction is still of concern, especially in the elderly patients, we conclude from these data that de-escalation of induction therapy in elderly primary central nervous system lymphoma patients followed by maintenance treatment seems to be a promising treatment strategy.

Published
2015
Full Text
View/download PDF

45. Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity

Author

Smeland, Knut B., Loge, Jon H., Aass, Hans C. D., Aspelin, Trude, Bersvendsen, Hanne, Bolstad, Nils, Fagerli, Unn-Merete, Falk, Ragnhild S., Fluge, Øystein, Fosså, Alexander, Holte, Harald, Lund, May B., Murbræch, Klaus, Reinertsen, Kristin V., Stenehjem, Jo S., and Kiserud, Cecilie E.

Published
2019
Full Text
View/download PDF

47. A national study on conditional survival and excess mortality after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Author

Smeland, Knut Bjøro, primary, Kiserud, Cecilie E, additional, Lauritzsen, Grete F, additional, Blystad, Anne Kirsti, additional, Fagerli, Unn-Merete, additional, Falk, Ragnhild Sorum, additional, Fluge, Oystein, additional, Fossa, Alexander, additional, Kolstad, Arne, additional, Loge, Jon Havard, additional, Maisenholder, Martin, additional, Kvaløy, Stein, additional, and Holte, Harald, additional

Published
2015
Full Text
View/download PDF

49. Nordic MCL-3 study : 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Author

Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Grønbæk, Kirsten, Elonen, Erkki, Räty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Kimby, Eva, Hansen, Per Boye, Fagerli, Unn Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundström, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, Geisler, Christian H, Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Grønbæk, Kirsten, Elonen, Erkki, Räty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Kimby, Eva, Hansen, Per Boye, Fagerli, Unn Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundström, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, and Geisler, Christian H

Abstract

The main objective of the MCL3 study was to improve outcome for patients not in CR before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. 160 consecutive, untreated stage II-IV MCL patients < 66 years received rituximab (R)- maxi-CHOP alternating with R-high-dose Ara-C (6 cycles total), followed by high-dose BEAM or BEAC and autologous stem cell transplantation 2005-2009. Zevalin (0.4 mCi/kg) was given to responders in only CRu/PR prior to high-dose therapy. The overall response rate (ORR) pre-transplant was 97%. After a median follow-up of 4.4 years the outcome did not differ from that of the historic control, the MCL2 trial with the same treatment except for Zevalin. Overall (OS), event free (EFS), and progression-free survival (PFS) at 4 years were 78, 62 and 71%, respectively. For patients in CRu/PR before transplant who received Zevalin duration of response was shorter than in the CR group. Inferior PFS, EFS- and OS were predicted by PET-positivity pre-transplant and detectable minimal residual disease (MRD) before and after transplant. In conclusion, a positive PET prior to transplant and MRD are strong predictors of outcome. Late intensification with Zevalin may be too late to improve the outcome of patients not in CR before transplant.

Published
2014
Full Text
View/download PDF

50. Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Author

Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Gronbaek, Kirsten, Elonen, Erkki, Raty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Kimby, Eva, Hansen, Per Boye, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundstrom, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, Geisler, Christian H., Kolstad, Arne, Laurell, Anna, Jerkeman, Mats, Gronbaek, Kirsten, Elonen, Erkki, Raty, Riikka, Pedersen, Lone Bredo, Loft, Annika, Bogsrud, Trond Velde, Kimby, Eva, Hansen, Per Boye, Fagerli, Unn-Merete, Nilsson-Ehle, Herman, Lauritzsen, Grete Fossum, Lehmann, Anne Kristine, Sundstrom, Christer, Karjalainen-Lindsberg, Marja-Liisa, Ralfkiaer, Elisabeth, Ehinger, Mats, Delabie, Jan, Bentzen, Hans, Schildt, Jukka, Kostova-Aherdan, Kamelia, Frederiksen, Henrik, Brown, Peter de Nully, and Geisler, Christian H.

Abstract

The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding 90 Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years received rituximab (R)-maxi-CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) alternating with R-high-dose cytarabine (6 cycles total), followed by high-dose BEAM/C (bis-chloroethylnitrosourea, etoposide, cytarabine, and melphalan or cyclophosphamide) and autologous stem cell transplantation from 2005 to 2009. Zevalin (0.4 mCi/kg) was given to responders not in CR before transplant. Overall response rate pretransplant was 97%. The outcome did not differ from that of the historic control: the MCL2 trial with similar treatment except for Zevalin. Overall survival (OS), event-free survival (EFS), and progression-free survival (PFS) at 4 years were 78%, 62%, and 71%, respectively. For responding non-CR patients who received Zevalin, duration of response was shorter than for the CR group. Inferior PFS, EFS, and OS were predicted by positron emission tomography (PET) positivity pretransplant and detectable minimal residual disease (MRD) after transplant. In conclusion, positive PET and MRD were strong predictors of outcome. Intensification with Zevalin may be too late to improve the outcome of patients not in CR before transplant. This trial was registered at www.clinicaltrials.gov as #NCT00514475.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results